ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

rosuvastatin

Also written as “Rosuvastatin”, “CKD-828, D097, D337” and “Rosuvastatin 20mg”.

Its studies are mostly in Hypercholesterolemia · Hypertension · Dyslipidemias · Hyperlipidemias · Coronary Artery Disease, led by 27 companies.

Drug pageRosuvastatin: every studyMany companies study it; this page follows only the 138 they lead. All 405 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 7, 2005138 company-led studies, 7 open or runningNext primary completion: Jan 25, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only705 open or runningphase 4since Oct 7, 2005Sep 16, 2005Jan 25, 2027phase 1 · NCT07534592
Yuhanits history only100 open or runningphase 4since Jul 12, 2017Jan 5, 2012none ahead
Chong Kun Dang Pharmaceuticalits history only80 open or runningphase 2since Nov 27, 2016Jan 24, 2014none ahead
Organonits history only60 open or runningphase 4since Mar 31, 2008Aug 25, 2004none ahead
GlaxoSmithKlineits history only40 open or runningphase 1since Dec 18, 2008Dec 18, 2008none ahead
Merckits history only40 open or runningphase 3since Oct 10, 2025Jun 17, 2015none ahead
Hanlim Pharm.its history only30 open or runningphase 3since Jun 17, 2018Jun 17, 2018none ahead
IlDong Pharmaceuticalits history only30 open or runningphase 3since Mar 5, 2014Mar 5, 2014none ahead
Jeil Pharmaceuticalits history only30 open or runningphase 3since Jun 23, 2016Jul 4, 2014none ahead
Lotus Pharmaceuticalits history only30 open or runningphase 3since May 13, 2015Mar 4, 2014none ahead
Daewon Pharmaceutical20 open or runningphase 3since Oct 12, 2016Oct 12, 2016none ahead

Also a collaborator on its studies: Parexel, Pharma Medica Research, Pfizer, Regeneron Pharmaceuticals, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene, Eli Lilly, Linical Korea and Shionogi.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Daewon Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 12, 2016First study: phase 3 study in HypertensionFirst studyNCT03210532 · 129 enrolled · Korea, Republic of
  2. Oct 12, 2016Phase 1 study in HypertensionNCT02933658 · 71 enrolled

TargetBeta

HMGCR →read by rule
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule

Other programs on HMGCR

ProgramCompanyFurthest phaseStudies
AtorvastatinruleViatrisphase 4186
SimvastatinruleOrganonphase 4100
pitavastatinruleKowaphase 436

Studies

All 2 Daewon Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03210532Hypertension · Korea, Republic of3CompletedSep 2017129
NCT02933658Hypertension1CompletedNov 201571

How it is read

Names in the registry

  • “Rosuvastatin”, 105 entries
  • “rosuvastatin”, 10 entries
  • “CKD-828, D097, D337”, 6 entries
  • “Rosuvastatin 20mg”, 6 entries
  • “Ezetimibe/Rosuvastatin”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.